We will be contrasting the differences between Provention Bio Inc. (NASDAQ:PRVB) and CRISPR Therapeutics AG (NASDAQ:CRSP) as far as institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Provention Bio Inc. 8 0.00 32.25M -0.93 0.00
CRISPR Therapeutics AG 56 0.00 34.37M -3.74 0.00

Table 1 showcases the gross revenue, earnings per share and valuation of Provention Bio Inc. and CRISPR Therapeutics AG.

Profitability

Table 2 provides us Provention Bio Inc. and CRISPR Therapeutics AG’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Provention Bio Inc. 393,772,893.77% -83.2% -67.8%
CRISPR Therapeutics AG 61,805,430.68% -50.9% -39.8%

Liquidity

Provention Bio Inc.’s Current Ratio and Quick Ratio are 17.5 and 17.5 respectively. The Current Ratio and Quick Ratio of its competitor CRISPR Therapeutics AG are 15.8 and 15.8 respectively. Provention Bio Inc. therefore has a better chance of paying off short and long-term obligations compared to CRISPR Therapeutics AG.

Analyst Recommendations

In next table is shown Provention Bio Inc. and CRISPR Therapeutics AG’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Provention Bio Inc. 0 0 0 0.00
CRISPR Therapeutics AG 0 0 4 3.00

Competitively the consensus target price of CRISPR Therapeutics AG is $66.5, which is potential -8.11% downside.

Institutional and Insider Ownership

Roughly 6.3% of Provention Bio Inc. shares are owned by institutional investors while 50% of CRISPR Therapeutics AG are owned by institutional investors. About 7.2% of Provention Bio Inc.’s share are owned by insiders. Comparatively, CRISPR Therapeutics AG has 2% of it’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Provention Bio Inc. -6.05% -15.92% 174.29% 361.64% 164% 496.61%
CRISPR Therapeutics AG 3.15% 6.25% 30.58% 57.23% 7.51% 77.42%

For the past year Provention Bio Inc. was more bullish than CRISPR Therapeutics AG.

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, oral CSF-1R inhibitor, which is in Phase 2a clinical trial for the treatment of Crohn's disease; PRV-300, anti-TLR3 mAb, which is in Phase 1b clinical trial for the treatment of ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101, a multivalent coxsackie virus vaccine for the prevention of acute Coxsackie Virus B Vaccine and the prevention of the onset of T1D. The company was incorporated in 2016 and is based in Oldwick, New Jersey.

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



Source link